Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tscan Therapeutics, Inc.

1.92
-0.1000-4.95%
Post-market: 1.89-0.0300-1.56%17:26 EST
Volume:309.21K
Turnover:600.13K
Market Cap:108.49M
PE:-0.92
High:2.04
Open:2.04
Low:1.87
Close:2.02
Loading ...

Company Profile

Company Name:
Tscan Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
194
Office Location:
830 Winter Street,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
David Southwell
President, Chief Executive Officer and Director
Timothy Barberich
Chairperson of the Board
Andrew Hedin
Director
Christoph Westphal
Director
Gabriela Gruia
Director
Ittai Harel
Director
Katina Dorton
Director
Nandita Shangari
Director
Stephen Biggar
Director

Shareholders

Name
Position
David Southwell
President, Chief Executive Officer and Director
Brian Silver
Senior Vice President and Chief Financial Officer
Gavin MacBeath
Chief Scientific Officer
William Desmarais
Chief Business Officer